The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Daikh, D. I.
Right arrow Articles by Wofsy, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Daikh, D. I.
Right arrow Articles by Wofsy, D.
The Journal of Immunology, 2001, 166: 2913-2916.
Copyright © 2001 by The American Association of Immunologists


CUTTING EDGE

Cutting Edge: Reversal of Murine Lupus Nephritis with CTLA4Ig and Cyclophosphamide1

David I. Daikh2 and David Wofsy

Department of Medicine, Department of Veterans Affairs Medical Center and the University of California, San Francisco, CA 94121

Cyclophosphamide (CTX) prevents progression of nephritis and prolongs survival in (NZB x NZW)F1 (B/W) mice and is used to treat humans with lupus nephritis. To compare the efficacy of CTLA4Ig with CTX and determine whether there is an incremental benefit to combining CTLA4Ig with CTX, we treated B/W mice with CTX, CTLA4Ig, or both agents. In mice with mild renal disease, treatment delayed the onset of proteinuria and prolonged survival in all groups. In mice with advanced renal disease, treatment with both agents reduced proteinuria in 71% of mice, whereas mice treated with either agent alone had no such improvement. Survival was also markedly improved among mice treated with both agents. Thus, combination treatment with CTX and CTLA4Ig is more effective than either agent alone in reducing renal disease and prolonging survival of B/W mice with advanced nephritis. This striking reversal of proteinuria is unprecedented in animal models of SLE.




This article has been cited by other articles:


Home page
J. Nutr.Home page
C. Chaudhury, J. Kim, S. Mehnaz, M. A. Wani, T. M. Oberyszyn, C. L. Bronson, S. Mohanty, W. L. Hayton, J. M. Robinson, and C. L. Anderson
Accelerated Transferrin Degradation in HFE-Deficient Mice Is Associated with Increased Transferrin Saturation
J. Nutr., December 1, 2006; 136(12): 2993 - 2998.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
G. C. Zeller, J. Hirahashi, A. Schwarting, A. H. Sharpe, and V. R. Kelley
Inducible Co-Stimulator Null MRL-Faslpr Mice: Uncoupling of Autoantibodies and T Cell Responses in Lupus
J. Am. Soc. Nephrol., January 1, 2006; 17(1): 122 - 130.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
A Davidson, B Diamond, D Wofsy, and D Daikh
Block and tackle: CTLA4Ig takes on lupus
Lupus, March 1, 2005; 14(3): 197 - 203.
[Abstract] [PDF]


Home page
LupusHome page
H Tahir and D A Isenberg
Novel therapies in lupus nephritis
Lupus, January 1, 2005; 14(1): 77 - 82.
[Abstract] [PDF]


Home page
LupusHome page
M Dall'Era and J Davis
CTLA4Ig: a novel inhibitor of costimulation
Lupus, May 1, 2004; 13(5): 372 - 376.
[Abstract] [PDF]


Home page
J. Am. Coll. Nutr.Home page
A. Bhattacharya, R. A. Lawrence, A. Krishnan, K. Zaman, D. Sun, and G. Fernandes
Effect of Dietary n-3 and n-6 Oils with and without Food Restriction on Activity of Antioxidant Enzymes and Lipid Peroxidation in Livers of Cyclophosphamide Treated Autoimmune-Prone NZB/W Female Mice
J. Am. Coll. Nutr., October 1, 2003; 22(5): 388 - 399.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
C C Mok, R W S Wong, and K N Lai
Treatment of severe proliferative lupus nephritis: the current state
Ann Rheum Dis, September 1, 2003; 62(9): 799 - 804.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. Schiffer, J. Sinha, X. Wang, W. Huang, G. von Gonsdorff, M. Schiffer, M. P. Madaio, and A. Davidson
Short Term Administration of Costimulatory Blockade and Cyclophosphamide Induces Remission of Systemic Lupus Erythematosus Nephritis in NZB/W F1 Mice by a Mechanism Downstream of Renal Immune Complex Deposition
J. Immunol., July 1, 2003; 171(1): 489 - 497.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
A. DAVIDSON, X. WANG, M. MIHARA, M. RAMANUJAM, W. HUANG, L. SCHIFFER, and J. SINHA
Co-Stimulatory Blockade in the Treatment of Murine Systemic Lupus Erythematosus (SLE)
Ann. N.Y. Acad. Sci., April 1, 2003; 987(1): 188 - 198.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. Balabanian, J. Couderc, L. Bouchet-Delbos, A. Amara, D. Berrebi, A. Foussat, F. Baleux, A. Portier, I. Durand-Gasselin, R. L. Coffman, et al.
Role of the Chemokine Stromal Cell-Derived Factor 1 in Autoantibody Production and Nephritis in Murine Lupus
J. Immunol., March 15, 2003; 170(6): 3392 - 3400.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
L E Schiffer, N Hussain, X Wang, W Huang, J Sinha, M Ramanujam, and A Davidson
Lowering anti-dsDNA antibodies--what's new?
Lupus, December 1, 2002; 11(12): 885 - 894.
[Abstract] [PDF]


Home page
LupusHome page
B H Hahn
Lessons in lupus: the mighty mouse
Lupus, September 1, 2001; 10(9): 589 - 593.
[PDF]


Home page
NEJMHome page
A. Davidson and B. Diamond
Autoimmune Diseases
N. Engl. J. Med., August 2, 2001; 345(5): 340 - 350.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2001 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2001 by The American Association of Immunologists, Inc. All rights reserved.